CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 229 enrolled
Drug / intervention
Aceclidine+Brimonidine combination ophthalmic solution +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05728944
NCT05728944Phase 3Completed
CompareCT.gov

A Multi-Center, Double-Masked Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia

LENZ Therapeutics, Inc·interventional·Posted Feb 15, 2023·Updated Feb 25, 2026

In Brief

A Phase 3 clinical trial evaluating Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, and 1 other intervention for Presbyopia and 3 related conditions. Completed, enrolled 229 participants across 17 sites.

Detailed Summary

Phase 3 Efficacy Study to evaluate the Safety and Efficacy of LNZ100 \& LNZ101 for the Treatment of Presbyopia

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPresbyopia, Near Vision, Refractive Error, Eye Diseases
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
202420252026
First PostedFeb 15, 2023
Enrollment StartMar 6, 2023
Primary CompletionDec 14, 2023
Study CompletionJan 24, 2024
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 3.4 years ago

Interventions

Aceclidine+Brimonidine combination ophthalmic solutiondrug

Aceclidine + Brimonidine combination ophthalmic solution

Aceclidine ophthalmic solutiondrug

Aceclidine ophthalmic solution

Vehicledrug

Proprietary vehicle ophthalmic solution